Canada - English - Health Canada

cobalt pharmaceuticals company - etidronate disodium - tablet - 400mg - etidronate disodium 400mg - bone resorption inhibitors

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - pamidronate disodium (unii: 8742t8zqza) (pamidronic acid - unii:oyy3447omc) - pamidronate disodium 3 mg in 1 ml - pamidronate disodium injection, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases.  patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium.  vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 l/day throughout treatment.  mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics).  patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided.  diuretic therapy should not be employed prior to correction of hypovolemia.  the safety and efficacy of pamidronate disodium injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-

United States - English - NLM (National Library of Medicine)

teva parenteral medicines, inc. - pamidronate disodium (unii: 8742t8zqza) (pamidronic acid - unii:oyy3447omc) - pamidronate disodium 3 mg in 1 ml - pamidronate disodium injection is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. pamidronate disodium injection is indicated for the treatment of patients with moderate to severe paget’s disease of bone. pamidronate disodium injection is indicated in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma [see clinical studies (14.3)] . the safety and efficacy of pamidronate disodium injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. pamidronate disodium is contraindicated in patients with hypersensitivity to pamidronate disodium, other bisphosphonates, or mannitol. reactions to pamidronate disodium injection and to mannitol have included anaphylaxis. pregnancy category d [see warnings and precautions (5.2)] risk summary there are no ad

Canada - English - Health Canada

teva canada limited - etidronate disodium - tablet - 200mg - etidronate disodium 200mg - bone resorption inhibitors

Canada - English - Health Canada

teva canada limited - etidronate disodium - tablet - 400mg - etidronate disodium 400mg - bone resorption inhibitors

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - disodium etidronate -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - disodium etidronate -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - disodium etidronate -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - disodium etidronate -

United States - English - NLM (National Library of Medicine)

akorn-strides, llc - pamidronate disodium (unii: 8742t8zqza) (pamidronic acid - unii:oyy3447omc) - injection - 3 mg in 1 ml - pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 l/day throughout treatment. mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. diuretic therapy should not be employed prior to correction of hypovolemia. the safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions h